The US Food and Drug Administration (FDA) authorized an in-feed sea lice treatment developed by Animal health research company Elanco that was approved for commercial use in Chile earlier this year.
The FDA found the active ingredient of the treatment, Lufenuron, has no significant impact on the quality of human environment, therefore allowing the imports of salmon treated with the product.
Chilean companies treating their fish with the Imvixa drug -- which prevents and controls sea lice presence for a prolonged period of time -- were already allowed to sell this fish domestically, and export it to Brazil, the European Union and Norway.
With
